Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Investing.com -- Novo Nordisk 's (CSE: NOVOb ) stock jumped over 3% on Wednesday following a stronger-than-expected ...

Ascendis Pharma AS (ASND) reports significant milestones and market traction, despite facing revenue and reimbursement hurdles.

Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

Novo Nordisk, however, forecast slower sales growth for 2025 of between 16% to ... work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors are now watching ...

We recently compiled a list of the 12 Best International Dividend Stocks To Buy Now. In this article, we are going to take a ...